comparemela.com
Home
Live Updates
Novartis shares positive late-stage results for Fabhalta in
Novartis shares positive late-stage results for Fabhalta in
Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy
Approximately one to two people per million worldwide are diagnosed with C3G every year
Related Keywords
,
David Soergel ,
David Kavanagh ,
Newcastle University ,
European Medicines Agency ,
Novartis ,
European Renal Association Congress ,
Drug Administration ,